ArticleThoracic cancer2016

Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

Hongyan Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.